TCL Archive In Brief: ACS to Spend Record $85 Million On Research: AACR To Honor Hanafusa, DeVita, Barbacid March 14, 1986
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004